Derik De Bruin
Stock Analyst at B of A Securities
(4.97)
# 12
Out of 4,827 analysts
210
Total ratings
65.73%
Success rate
87.85%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $4.03 | +172.95% | 13 | Mar 3, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $72 → $65 | $53.06 | +22.50% | 7 | Feb 20, 2025 | |
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $8.13 | +96.80% | 5 | Feb 19, 2025 | |
| WAT Waters | Maintains: Neutral | $430 → $410 | $350.88 | +16.85% | 13 | Feb 13, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $156 | $108.70 | +43.51% | 32 | Jan 27, 2025 | |
| RVTY Revvity | Upgrades: Buy | $138 | $92.90 | +48.55% | 2 | Dec 13, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $675 → $660 | $410.78 | +60.67% | 18 | Dec 13, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $235 | $153.29 | +53.30% | 3 | Dec 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $220 → $210 | $141.36 | +48.56% | 5 | Dec 13, 2024 | |
| WST West Pharmaceutical Services | Maintains: Buy | $350 → $355 | $214.74 | +65.32% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $22.48 | +15.66% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $248.76 | +8.94% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $175.90 | +3.47% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $40.51 | +97.48% | 12 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $194.82 | +48.86% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $22.25 | -32.58% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $5.95 | +252.94% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $25 | $8.63 | +189.69% | 8 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $23.88 | +34.00% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $79.58 | +25.66% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $56.18 | +53.08% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.91 | +232.48% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,101.63 | +38.43% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.89 | +243.92% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $138.48 | +87.75% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $7.87 | +1,424.78% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 | $42.16 | +48.46% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $161.69 | -25.78% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.25 | +300.00% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $489.98 | -52.04% | 3 | Nov 2, 2018 |
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $4.03
Upside: +172.95%
Exact Sciences
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $53.06
Upside: +22.50%
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $8.13
Upside: +96.80%
Waters
Feb 13, 2025
Maintains: Neutral
Price Target: $430 → $410
Current: $350.88
Upside: +16.85%
Agilent Technologies
Jan 27, 2025
Maintains: Neutral
Price Target: $150 → $156
Current: $108.70
Upside: +43.51%
Revvity
Dec 13, 2024
Upgrades: Buy
Price Target: $138
Current: $92.90
Upside: +48.55%
Thermo Fisher Scientific
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $410.78
Upside: +60.67%
IQVIA Holdings
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $153.29
Upside: +53.30%
Charles River Laboratories International
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $141.36
Upside: +48.56%
West Pharmaceutical Services
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $214.74
Upside: +65.32%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $22.48
Upside: +15.66%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $248.76
Upside: +8.94%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $175.90
Upside: +3.47%
Dec 13, 2024
Maintains: Buy
Price Target: $78 → $80
Current: $40.51
Upside: +97.48%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $194.82
Upside: +48.86%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $22.25
Upside: -32.58%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $5.95
Upside: +252.94%
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $8.63
Upside: +189.69%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $23.88
Upside: +34.00%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $79.58
Upside: +25.66%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $56.18
Upside: +53.08%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.91
Upside: +232.48%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,101.63
Upside: +38.43%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.89
Upside: +243.92%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $138.48
Upside: +87.75%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $7.87
Upside: +1,424.78%
Oct 6, 2020
Upgrades: Buy
Price Target: $63
Current: $42.16
Upside: +48.46%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $161.69
Upside: -25.78%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.25
Upside: +300.00%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $489.98
Upside: -52.04%